Blog | HemaCare

Happy New Year! The Top 10 HemaCare Blogs of 2018

Dec 28, 2018 9:51:00 AM / by Nancy Andon, MSc

End of Year 2018_AdobeStock_180040993-12018 has flown by, and 2019 is just around the corner! As the New Year approaches, it’s good to look back at just how much has been accomplished in the field of medicine, and wonder what the future holds. As is our tradition at this time of year, we are pleased to present HemaCare’s 10 most popular blogs of the year, and the advances in healthcare that they represent. Enjoy the countdown!

 

  1. Advances in Immunotherapy May Change Glioblastoma Treatments

Combining checkpoint inhibitor cancer immunotherapy with CAR-T cell approaches that target interleukin (IL)-13R2a has proven to be more effective for treating glioblastoma than using either treatment alone.

  1. T Cells Can Help Reduce Inflammation in Autoimmune Conditions

“Bystander” T cells have recently been shown to counteract the inflammatory actions of antigen-specific cytotoxic T cells. Their presence can help limit tissue damage in autoimmune disease.

  1. What Are the Benefits to Using Disease State Samples?

This blog highlights how the availability of disease state cells and tissue samples helps scientists characterize the cellular and molecular features of a disease and its progression. Identifying biomarkers linked to early disease detection can improve disease management and prognosis.

  1. Cell Cryopreservation: Key to Optimal Cell Therapy Development and Application

Cryopreserving cells can be used to preserve therapeutic efficacy during shipping and storage, as well as providing on-demand treatment availability and consistency.

  1. Treating Glioblastoma with CAR-T Immunotherapy

Glioblastoma is a form of cancer which is very difficult to treat since tumors have mixed cell populations. Recent immunotherapy strategies are having promising results.

  1. Dendritic Cells Change Game for Immunotherapy for Cancer Patients

Dendritic cell-based anticancer vaccines have the potential to significantly increase cancer survival rates and improve the quality of life and function with fewer adverse effects.

  1. HemaCare Publication Illustrates Optimal Apheresis Collection Techniques

This blog features a new HemaCare publication in the popular online regenerative medicine journal RegMedNet. The article covers how to optimize various aspects of apheresis and cell collection in order to improve cell and gene therapy starting material quality. Donor networks, process development, apheresis devices, and quality management systems are discussed.

  1. HemaCare to supply pre-screened PBMCs to facilitate engraftment of human cells for Charles River’s new NCG mouse humanization kit

HemaCare and Charles River have partnered to create a new mouse humanization kit using         PBMCs preselected for rapid engraftment in the NCG mouse model.

  1. New Cancer Immunotherapy Approach Seeks to Supercharge T Cell Activity

HemaCare leukopaks are being used in a study focused on using an engineered fusion protein to enhance T cell activation, signaling, and proliferation. This fusion protein is now being evaluated in a multi-center Phase-1 clinical trial in human cancer patients with solid tumors.

 

And finally, our #1 blog post from 2018... drum roll please:

  1. How to Optimize Material Quality for Cellular Therapeutics

Our most popular blog post for 2018 focused on one of the most important aspects of cell and gene therapy; optimizing starting material quality and consistency. We present important tips on apheresis training, cell collection, and preserving cell viability and function.

We hope you enjoy checking out these blogs, and that the New Year brings many more fascinating medical advances. HemaCare wishes all of you a healthy and happy 2019!

Topics: immunotherapy, T cells, cancer treatment, CAR T cells

Nancy Andon, MSc

Written by Nancy Andon, MSc

Subscribe Here!

Posts by Topic

see all

Recent Posts